Advanced Breast Cancer
240
70
89
68
Key Insights
Highlights
Success Rate
80% trial completion
Published Results
35 trials with published results (15%)
Research Maturity
68 completed trials (28% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
7.1%
17 terminated out of 240 trials
80.0%
-6.5% vs benchmark
13%
30 trials in Phase 3/4
51%
35 of 68 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 68 completed trials
Clinical Trials (240)
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Timing of ctDNA Testing in Advanced Breast Cancer
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
Decision Support Tool for Patients With Advanced Breast Cancer
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer